Plant Name: Panax quinquefolius
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| TSHR; | |
| FFAR1; FFAR4; | |
| PDE10A; | |
| PDE3B; PDE3A; | |
| PDE2A; | |
| PDE5A; | |
| GAA; BCHE; ACHE; | |
| FAAH; TDP1; TERT; HPGD; ALOX12; AKR1B1; AKR1B10; ALOX15; ALDH1A1; USP2; | |
| KCNH2; | |
| PPARA; PPARD; PPARG; | |
| NR1I2; | |
| PTGS1; | |
| TLR2; | |
| HIF1A; NFKB1; | |
| CREBBP; | |
| SLC22A8; SLC22A6; | |
| LMNA; RAD52; FABP3; FABP5; FABP2; FABP4; | |
| SMN1;SMN2; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Bromodomain | CREBBP | CREB-binding protein | Q92793 | CHEMBL5747 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| Enzyme_unclassified | USP2 | Ubiquitin carboxyl-terminal hydrolase 2 | O75604 | CHEMBL1293227 |
| Enzyme_unclassified | FAAH | Anandamide amidohydrolase | O00519 | CHEMBL2243 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | TERT | Telomerase reverse transcriptase | O14746 | CHEMBL2916 |
| Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
| Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | AKR1B10 | Aldo-keto reductase family 1 member B10 | O60218 | CHEMBL5983 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
| Hydrolase | BCHE | Butyrylcholinesterase | P06276 | CHEMBL1914 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
| Nuclear hormone receptor subfamily 1 group C | PPARD | Peroxisome proliferator-activated receptor delta | Q03181 | CHEMBL3979 |
| Nuclear hormone receptor subfamily 1 group C | PPARG | Peroxisome proliferator-activated receptor gamma | P37231 | CHEMBL235 |
| Nuclear hormone receptor subfamily 1 group I | NR1I2 | Pregnane X receptor | O75469 | CHEMBL3401 |
| Oxidoreductase | PTGS1 | Cyclooxygenase-1 | P23219 | CHEMBL221 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Phosphodiesterase 10 | PDE10A | Phosphodiesterase 10A | Q9Y233 | CHEMBL4409 |
| Phosphodiesterase 2 | PDE2A | Phosphodiesterase 2A | O00408 | CHEMBL2652 |
| Phosphodiesterase 3 | PDE3B | Phosphodiesterase 3B | Q13370 | CHEMBL290 |
| Phosphodiesterase 3 | PDE3A | Phosphodiesterase 3A | Q14432 | CHEMBL241 |
| Phosphodiesterase 5 | PDE5A | Phosphodiesterase 5A | O76074 | CHEMBL1827 |
| Potassium channels | KCNH2 | HERG | Q12809 | CHEMBL240 |
| SLC superfamily of solute carriers | SLC22A8 | Solute carrier family 22 member 8 | Q8TCC7 | CHEMBL1641348 |
| SLC superfamily of solute carriers | SLC22A6 | Solute carrier family 22 member 6 | Q4U2R8 | CHEMBL1641347 |
| Small molecule receptor (family A GPCR) | FFAR1 | Free fatty acid receptor 1 | O14842 | CHEMBL4422 |
| Small molecule receptor (family A GPCR) | FFAR4 | G-protein coupled receptor 120 | Q5NUL3 | CHEMBL5339 |
| Toll-like and Il-1 receptors | TLR2 | Toll-like receptor 2 | O60603 | CHEMBL4163 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | RAD52 | DNA repair protein RAD52 homolog | P43351 | CHEMBL2362978 |
| Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
| Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
| Unclassified | FABP2 | Fatty acid binding protein intestinal | P12104 | CHEMBL4879 |
| Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0003824; catalytic activity | GO:0047555; 3',5'-cyclic-GMP phosphodiesterase activity | 1.075E-10 | 1.801E-07 | PDE10A, PDE2A, PDE3A, PDE3B, PDE5A |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 3.841E-10 | 4.647E-07 | CYP1A2, CYP2C19, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0006805; xenobiotic metabolic process | 7.808E-09 | 5.484E-06 | BCHE, CYP1A2, CYP2C19, CYP2D6, CYP3A4, NR1I2, PTGS1 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 1.255E-08 | 7.589E-06 | CYP1A2, CYP2C19, CYP3A4, NR1I2 |
| BP | GO:0008152; metabolic process | GO:0006198; cAMP catabolic process | 2.529E-08 | 1.311E-05 | PDE10A, PDE2A, PDE3A, PDE3B |
| MF | GO:0003824; catalytic activity | GO:0004115; 3',5'-cyclic-AMP phosphodiesterase activity | 3.442E-08 | 1.630E-05 | PDE10A, PDE2A, PDE3A, PDE3B |
| BP | GO:0008152; metabolic process | GO:0008202; steroid metabolic process | 9.146E-08 | 3.873E-05 | AKR1B1, AKR1B10, CYP1A2, CYP2C19, CYP2D6, CYP3A4, NR1I2, PPARD |
| BP | GO:0008152; metabolic process | GO:0046069; cGMP catabolic process | 2.352E-07 | 8.828E-05 | PDE10A, PDE2A, PDE5A |
| BP | GO:0008152; metabolic process | GO:0019433; triglyceride catabolic process | 3.136E-07 | 1.120E-04 | FABP2, FABP3, FABP4, FABP5 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 1.834E-06 | 5.324E-04 | ALOX12, ALOX15, CYP1A2, CYP2C19, CYP2D6, CYP3A4 |
| BP | GO:0065007; biological regulation | GO:0010817; regulation of hormone levels | 2.174E-06 | 5.992E-04 | ACHE, AKR1B1, ALDH1A1, CYP3A4, FFAR1, FFAR4, HIF1A, NFKB1, PPARD |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 2.561E-06 | 6.942E-04 | CYP1A2, CYP2D6, CYP3A4 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 3.571E-06 | 9.041E-04 | CYP1A2, CYP2C19, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 5.307E-06 | 1.191E-03 | ALOX12, ALOX15 |
| MF | GO:0140110; transcription regulator activity | GO:0004879; nuclear receptor activity | 5.043E-06 | 1.191E-03 | NR1I2, PPARA, PPARD, PPARG |
| MF | GO:0005488; binding | GO:0030553; cGMP binding | 5.272E-06 | 1.191E-03 | PDE10A, PDE2A, PDE5A |
| MF | GO:0003824; catalytic activity | GO:0003990; acetylcholinesterase activity | 5.307E-06 | 1.191E-03 | ACHE, BCHE |
| MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 5.307E-06 | 1.191E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0004119; cGMP-inhibited cyclic-nucleotide phosphodiesterase activity | 5.307E-06 | 1.191E-03 | PDE3A, PDE3B |
| BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 6.478E-06 | 1.411E-03 | ALOX12, ALOX15, HPGD |
| BP | GO:0050896; response to stimulus | GO:0050728; negative regulation of inflammatory response | 6.924E-06 | 1.478E-03 | FFAR4, NFKB1, PPARA, PPARD, PPARG |
| MF | GO:0060089; molecular transducer activity | GO:0003707; steroid hormone receptor activity | 1.065E-05 | 2.209E-03 | NR1I2, PPARA, PPARD, PPARG |
| BP | GO:0008283; cell proliferation | GO:0048660; regulation of smooth muscle cell proliferation | 1.167E-05 | 2.353E-03 | AKR1B1, HPGD, PPARD, PPARG, TERT |
| MF | GO:0005488; binding | GO:0020037; heme binding | 1.167E-05 | 2.353E-03 | CYP1A2, CYP2C19, CYP2D6, CYP3A4, PTGS1 |
| BP | GO:0008152; metabolic process | GO:0009822; alkaloid catabolic process | 1.590E-05 | 2.934E-03 | CYP2D6, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 1.590E-05 | 2.934E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0004118; cGMP-stimulated cyclic-nucleotide phosphodiesterase activity | 1.590E-05 | 2.934E-03 | PDE10A, PDE2A |
| MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 1.590E-05 | 2.934E-03 | ALOX12, ALOX15 |
| BP | GO:0050896; response to stimulus | GO:0032868; response to insulin | 1.740E-05 | 3.158E-03 | FABP3, PDE3B, PPARA, PPARG, TLR2 |
| BP | GO:0051179; localization | GO:0015908; fatty acid transport | 1.770E-05 | 3.185E-03 | FABP3, PPARA, PPARD, PPARG |
| MF | GO:0005488; binding | GO:0030552; cAMP binding | 2.025E-05 | 3.586E-03 | PDE10A, PDE2A, PDE3A |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 2.025E-05 | 3.586E-03 | CYP1A2, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0046483; heterocycle metabolic process | 2.280E-05 | 3.972E-03 | ACHE, ALOX12, BCHE, CREBBP, CYP1A2, CYP2C19, CYP2D6, CYP3A4, HIF1A, NFKB1, NR1I2, PDE10A, PDE2A, PDE3A, PDE3B, PDE5A, PPARA, PPARD, PPARG, RAD52, SMN1, SMN2, TDP1, TERT |
| BP | GO:0009987; cellular process | GO:0060282; positive regulation of oocyte development | 3.175E-05 | 5.237E-03 | PDE3A, PDE5A |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 3.175E-05 | 5.237E-03 | CYP1A2, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0006367; transcription initiation from RNA polymerase II promoter | 3.424E-05 | 5.500E-03 | CREBBP, NR1I2, PPARA, PPARD, PPARG |
| BP | GO:0032501; multicellular organismal process | GO:0051241; negative regulation of multicellular organismal process | 3.458E-05 | 5.500E-03 | ALOX12, FFAR4, HIF1A, LMNA, NFKB1, PDE3B, PDE5A, PPARD, PPARG, TERT, TLR2 |
| BP | GO:0050896; response to stimulus | GO:0070542; response to fatty acid | 3.572E-05 | 5.619E-03 | FABP3, FFAR1, PPARG, TLR2 |
| BP | GO:0050896; response to stimulus | GO:0014070; response to organic cyclic compound | 3.786E-05 | 5.846E-03 | BCHE, CYP1A2, HPGD, NFKB1, PDE2A, PDE3A, PPARG, SLC22A6, TLR2 |
| BP | GO:0008152; metabolic process | GO:0006691; leukotriene metabolic process | 5.074E-05 | 7.276E-03 | ALOX12, ALOX15, TLR2 |
| BP | GO:0008152; metabolic process | GO:0051122; hepoxilin biosynthetic process | 5.283E-05 | 7.328E-03 | ALOX12, ALOX15 |
| BP | GO:0051179; localization | GO:0010891; negative regulation of sequestering of triglyceride | 5.283E-05 | 7.328E-03 | PPARA, PPARG |
| MF | GO:0005488; binding | GO:0042802; identical protein binding | 5.865E-05 | 7.932E-03 | ACHE, BCHE, HPGD, KCNH2, NFKB1, PDE2A, PPARG, RAD52, SLC22A6, SMN1, SMN2, TERT, USP2 |
| MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 6.722E-05 | 8.925E-03 | CYP2C19, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0016101; diterpenoid metabolic process | 7.603E-05 | 9.854E-03 | AKR1B10, ALDH1A1, PDE3A, PPARD |
| BP | GO:0051179; localization | GO:0010887; negative regulation of cholesterol storage | 7.913E-05 | 9.924E-03 | PPARA, PPARG |
| BP | GO:0008152; metabolic process | GO:0010871; negative regulation of receptor biosynthetic process | 7.913E-05 | 9.924E-03 | PPARA, PPARG |
| BP | GO:0050896; response to stimulus | GO:0071321; cellular response to cGMP | 7.913E-05 | 9.924E-03 | PDE2A, PDE3A |
| MF | GO:0005488; binding | GO:0050543; icosatetraenoic acid binding | 7.913E-05 | 9.924E-03 | FABP3, PPARG |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa03320 | PPAR signaling pathway_Homo sapiens_hsa03320 | 1.741E-10 | 2.054E-08 | FABP2; FABP3; FABP4; FABP5; PPARG; PPARA; PPARD |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 5.096E-07 | 3.007E-05 | CYP1A2; ALOX15; CYP3A4; CYP2C19 |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 5.306E-06 | 1.565E-04 | CREBBP; PDE3B; PDE3A; PPARA; NFKB1; TSHR |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 5.144E-06 | 1.565E-04 | CYP2D6; ALOX15; ALOX12; CYP2C19; PTGS1 |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 7.540E-06 | 1.779E-04 | FABP4; PDE3B; TSHR; PTGS1 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 1.134E-05 | 2.230E-04 | ALOX15; ALOX12; CYP2C19; PTGS1 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 1.737E-05 | 2.928E-04 | CYP2D6; CYP1A2; CYP3A4; CYP2C19 |
| hsa00230 | Purine metabolism_Homo sapiens_hsa00230 | 4.580E-05 | 6.005E-04 | PDE10A; PDE2A; PDE3B; PDE3A; PDE5A |
| hsa05032 | Morphine addiction_Homo sapiens_hsa05032 | 5.181E-05 | 6.113E-04 | PDE10A; PDE3B; PDE2A; PDE3A |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 3.489E-04 | 3.743E-03 | AKR1B10; GAA; CYP1A2; ALOX15; ALDH1A1; AKR1B1; ALOX12; CYP2C19; CYP3A4; PTGS1 |
| hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 4.142E-05 | 6.005E-04 | AKR1B10; GAA; AKR1B1 |
| hsa04022 | cGMP-PKG signaling pathway_Homo sapiens_hsa04022 | 5.350E-04 | 4.857E-03 | PDE2A; PDE3B; PDE3A; PDE5A |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 4.217E-04 | 4.147E-03 | CYP1A2; ALDH1A1; CYP3A4 |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 1.912E-03 | 1.253E-02 | CREBBP; PPARG; HIF1A; NFKB1; PPARD |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 5.930E-04 | 4.998E-03 | CYP2D6; CYP1A2; CYP3A4 |
| hsa04922 | Glucagon signaling pathway_Homo sapiens_hsa04922 | 1.521E-03 | 1.117E-02 | CREBBP; PDE3B; PPARA |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 1.609E-03 | 1.117E-02 | CREBBP; HIF1A; NFKB1 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 8.325E-04 | 6.549E-03 | CYP1A2; CYP3A4; CYP2C19 |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 4.321E-03 | 2.428E-02 | CREBBP; NFKB1; TLR2 |
| hsa05152 | Tuberculosis_Homo sapiens_hsa05152 | 7.478E-03 | 3.412E-02 | CREBBP; NFKB1; TLR2 |
| hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 7.710E-03 | 3.412E-02 | HPGD; PPARG; NFKB1 |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 7.303E-03 | 3.412E-02 | NFKB1; PPARD |
| hsa05168 | Herpes simplex infection_Homo sapiens_hsa05168 | 8.309E-03 | 3.502E-02 | CREBBP; NFKB1; TLR2 |
| hsa05134 | Legionellosis_Homo sapiens_hsa05134 | 6.815E-03 | 3.412E-02 | NFKB1; TLR2 |
| hsa00561 | Glycerolipid metabolism_Homo sapiens_hsa00561 | 7.807E-03 | 3.412E-02 | AKR1B10; AKR1B1 |
| hsa04924 | Renin secretion_Homo sapiens_hsa04924 | 9.134E-03 | 3.689E-02 | PDE3B; PDE3A |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 7.554E-03 | 3.412E-02 | CYP1A2; CYP3A4 |
| hsa00040 | Pentose and glucuronate interconversions_Homo sapiens_hsa00040 | 2.971E-03 | 1.753E-02 | AKR1B10; AKR1B1 |
| hsa05321 | Inflammatory bowel disease (IBD)_Homo sapiens_hsa05321 | 9.411E-03 | 3.689E-02 | NFKB1; TLR2 |
| hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 9.691E-03 | 3.689E-02 | CREBBP; HIF1A |
| hsa04920 | Adipocytokine signaling pathway_Homo sapiens_hsa04920 | 1.085E-02 | 3.887E-02 | PPARA; NFKB1 |
| hsa05140 | Leishmaniasis_Homo sapiens_hsa05140 | 1.176E-02 | 3.963E-02 | NFKB1; TLR2 |
| hsa00051 | Fructose and mannose metabolism_Homo sapiens_hsa00051 | 2.352E-03 | 1.461E-02 | AKR1B10; AKR1B1 |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 1.115E-02 | 3.887E-02 | SLC22A8; CYP3A4 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 1.120E-02 | 3.887E-02 | CYP1A2 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PDE2A; PTGS1; PPARG |
| E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | PTGS1 |
| NA: NA | Dyslipidemia | NA | PPARD |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dyslipidaemias | E78 | PPARD; PPARD |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | PTGS1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | TLR2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | PPARG |
| NA: NA | Rheumatold arthritis | NA | PTGS1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | FFAR1; NFKB1; PPARD; PPARG; PPARG |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | PPARD; NR1I2 |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | PDE5A |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| C00-D49: Neoplasms | Tumors | C00-D48 | TERT |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | PPARD; PPARG |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE |
| NA: NA | Upper abdominal bloating | NA | ACHE |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | PTGS1 |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | PPARG |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6 |
| C00-D49: Neoplasms | Chronic myeloid leukemia | NA | CREBBP |
| C00-D49: Neoplasms | Prostate cancer | C61 | TLR2; TERT |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Erectile dysfunction | F52.2, N48.4 | PDE5A; PDE5A |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | AKR1B1; TERT |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | TERT |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | PPARD |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | FFAR1; AKR1B1; PPARG |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dietary shortage | E40-E46 | PTGS1 |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | PTGS1 |
| C00-D49: Neoplasms | Cancer | C00-C96 | HIF1A; NFKB1; TLR2; ACHE |
| C00-D49: Neoplasms | Melanoma | C43 | TLR2; TERT |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1; ACHE |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; PPARG |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1; PTGS1 |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | CYP2D6 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | HIF1A; TLR2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | FAAH |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Huntington's disease | F02.2, G10 | PDE10A |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| H00-H59: Diseases of the eye and adnexa | Ocular inflammation | H16.229 | TERT; PPARG |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | PDE5A |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | FAAH |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | PDE5A; PDE5A |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | PTGS1 |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE |
| C00-D49: Neoplasms | Liver cancer | C22 | TERT |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Postoperative inflammation | T81 | PTGS1 |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
| C00-D49: Neoplasms | Ovarian cancer | C56 | TERT |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | PDE5A |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | FAAH; PTGS1 |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Radiation sickness | T66 | TLR2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CYP2D6 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | TLR2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Nicotine dependence | F17 | PPARG |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | PPARD |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | CREBBP; TERT |
| NA: NA | Raynaud's disease | NA | PDE5A; PDE5A |
| C00-D49: Neoplasms | Breast cancer | C50 | TERT |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PPARD; PPARD; PPARG |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | FFAR1 |
| K00-K95: Diseases of the digestive system | Non-alcoholic fatty liver disease | K76.0 | PPARD; PPARG |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| NA: NA | Miosis during ocular surgery | NA | PTGS1 |
| I00-I99: Diseases of the circulatory system | Angina pectoris | I20 | PDE5A |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; ACHE; FAAH |
| NA: NA | Schizoaffective disorder | NA | PDE10A |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | AKR1B1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | PDE10A; PDE10A |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | PDE5A; PTGS1 |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | PPARD |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | TLR2; TERT |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ACHE; FAAH; PTGS1 |
| C00-D49: Neoplasms | Multiple myeloma | C90 | TERT |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Anesthesia | R20.0 | FAAH |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | PTGS1 |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; ACHE; ACHE; PPARG; PPARG |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | PDE2A |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Spasm | R25.2 | PDE5A |